No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy

Direct-acting antiviral (DAA)-based therapy is the new standard treatment for chronic hepatitis C virus (HCV) infection. However, protease inhibitor (PI)-resistant viral variants have been often described. This study aimed to examine HCV-NS3 protease variants at baseline and at 4 weeks under triple...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffmann, Luísa, Faffe, Débora Souza, Lima, Jennifer Fróes Cruz, Capitanio, Thayanna Araujo, Cabral, Bianca Catarina Azeredo, Ürményi, Turán Péter, Coelho, Henrique Sergio Moraes, Rondinelli, Edson, Villela-Nogueira, Cristiane Alves, Silva, Rosane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661554/
https://www.ncbi.nlm.nih.gov/pubmed/26674563
http://dx.doi.org/10.1016/j.bbacli.2015.01.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661554/
https://www.ncbi.nlm.nih.gov/pubmed/26674563
http://dx.doi.org/10.1016/j.bbacli.2015.01.004

Ejemplares similares